Newsroom | Novo Nordisk
Here journalists can access a concise and up-to-date overview of our company’s key facts, figures, and milestones.
www.novonordisk.comHere are the latest semaglutide news highlights I found across reputable sources:
-
Novo Nordisk has released updates suggesting semaglutide may be effective against liver disease associated with obesity and overweight, with upcoming data expected to address broader metabolic benefits. This was highlighted by Novo Nordisk in their latest newsroom communications. [Source: Novo Nordisk newsroom, 2026-05-18]
-
The SOUL trial for oral semaglutide (Rybelsus) reported cardiovascular event reductions in patients with established cardiovascular disease, potentially expanding oral GLP-1 options for some patients. This was discussed in recent industry analyses and podcasts summarizing trial results. [Source: podcast summary on semaglutide updates, 2024-11-13]
-
Industry press and market coverage through 2025–2026 note ongoing expansion plans for semaglutide therapies, including potential launches in new regions and the progression of oral and injectable formulations through Phase III and regulatory review. [Source: Economic Times coverage referencing Phase III trials and potential future launches, 2025-08-22]
-
In clinical research, updates through 2026 point to broader applications beyond weight management, including potential benefits for liver disease and metabolic conditions, with continued interest from researchers and payers in widening access. [Source: Dose GLP-1 news digest, 2026-04-18]
-
Public safety and regulatory monitoring continue for semaglutide products, including concerns around compounded or counterfeit formulations and ongoing pharmacovigilance updates. Patients and clinicians are advised to verify product sourcing and authenticity. [Source: novoMEDLINK patient safety updates, 2024-12-17]
If you’d like, I can narrow this to:
- any updates specifically about Wegovy (weight management) vs Ozempic (diabetes) vs Mounjaro (tirzepatide, for comparison),
- regional developments (e.g., Europe, India, Canada),
- or a short synthesis of cardiovascular and liver disease data related to semaglutide with key trial names and dates.